These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21666286)

  • 1. Thioaptamer conjugated liposomes for tumor vasculature targeting.
    Mann AP; Bhavane RC; Somasunderam A; Liz Montalvo-Ortiz B; Ghaghada KB; Volk D; Nieves-Alicea R; Suh KS; Ferrari M; Annapragada A; Gorenstein DG; Tanaka T
    Oncotarget; 2011 Apr; 2(4):298-304. PubMed ID: 21666286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting.
    Mann AP; Somasunderam A; Nieves-Alicea R; Li X; Hu A; Sood AK; Ferrari M; Gorenstein DG; Tanaka T
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.
    Mai J; Huang Y; Mu C; Zhang G; Xu R; Guo X; Xia X; Volk DE; Lokesh GL; Thiviyanathan V; Gorenstein DG; Liu X; Ferrari M; Shen H
    J Control Release; 2014 Aug; 187():22-9. PubMed ID: 24818768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioaptamer-conjugated CD44-targeted delivery system for the treatment of breast cancer in vitro and in vivo.
    Fan W; Wang X; Ding B; Cai H; Wang X; Fan Y; Li Y; Liu S; Nie S; Lu Q
    J Drug Target; 2016; 24(4):359-71. PubMed ID: 26299192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
    Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
    Yao J; Feng J; Gao X; Wei D; Kang T; Zhu Q; Jiang T; Wei X; Chen J
    Biomaterials; 2017 Jan; 113():1-17. PubMed ID: 27794222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
    Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is nanomedicine still promising?
    Peiris PM; Karathanasis E
    Oncotarget; 2011 Jun; 2(6):430-2. PubMed ID: 21677362
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
    Li X; Wu M; Pan L; Shi J
    Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.
    Jin X; Li M; Yin L; Zhou J; Zhang Z; Lv H
    Nanomedicine; 2017 Apr; 13(3):1105-1115. PubMed ID: 27845234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
    Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
    Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
    Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
    Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aptamer-functionalized liposomes for targeted cancer therapy.
    Moosavian SA; Sahebkar A
    Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.